GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Phoenix Biotech Acquisition Corp (NAS:PBAX) » Definitions » ROC (Joel Greenblatt) %

Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) ROC (Joel Greenblatt) % : -21.89% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Phoenix Biotech Acquisition ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Phoenix Biotech Acquisition's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -21.89%.

The historical rank and industry rank for Phoenix Biotech Acquisition's ROC (Joel Greenblatt) % or its related term are showing as below:

PBAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -48.59   Med: -48.59   Max: -39.38
Current: -39.38

During the past 2 years, Phoenix Biotech Acquisition's highest ROC (Joel Greenblatt) % was -39.38%. The lowest was -48.59%. And the median was -48.59%.

PBAX's ROC (Joel Greenblatt) % is not ranked
in the Diversified Financial Services industry.
Industry Median: -22.69 vs PBAX: -39.38

Phoenix Biotech Acquisition's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Phoenix Biotech Acquisition ROC (Joel Greenblatt) % Historical Data

The historical data trend for Phoenix Biotech Acquisition's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phoenix Biotech Acquisition ROC (Joel Greenblatt) % Chart

Phoenix Biotech Acquisition Annual Data
Trend Dec21 Dec22
ROC (Joel Greenblatt) %
- -48.59

Phoenix Biotech Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,772.41 -43.65 -20.17 -55.20 -21.89

Competitive Comparison of Phoenix Biotech Acquisition's ROC (Joel Greenblatt) %

For the Shell Companies subindustry, Phoenix Biotech Acquisition's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phoenix Biotech Acquisition's ROC (Joel Greenblatt) % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Phoenix Biotech Acquisition's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Phoenix Biotech Acquisition's ROC (Joel Greenblatt) % falls into.



Phoenix Biotech Acquisition ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 14.005) - (3.236 + 0 + -8.8817841970013E-16)
=10.769

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 8.352) - (3.406 + 0 + 0)
=4.946

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Phoenix Biotech Acquisition for the quarter that ended in Sep. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.72/( ( (0 + max(10.769, 0)) + (0 + max(4.946, 0)) )/ 2 )
=-1.72/( ( 10.769 + 4.946 )/ 2 )
=-1.72/7.8575
=-21.89 %

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phoenix Biotech Acquisition  (NAS:PBAX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Phoenix Biotech Acquisition ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Phoenix Biotech Acquisition's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
2201 Broadway, Suite 705, Oakland, CA, USA, 94612
Website
Phoenix Biotech Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company intends to pursue an acquisition opportunity in any business, industry, sector or geographical location, industries that complement management team's background, and to capitalize on the ability of management team to identify and acquire a business in the healthcare or healthcare related industries in the United States and Europe.
Executives
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kathleen Laporte director
Christopher B Ehrlich director, 10 percent owner, officer: CEO and and Secretary 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Douglas Fisher officer: President 587 PATROL RD, WOODSIDE CA 94062
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Phoenix Biotech Sponsor, Llc 10 percent owner 2001 MARKET STREET, SUITE 3400, PHILADELPHIA PA 19103